Efficacy of Postoperative Transarterial Chemoembolization and Portal Vein Chemotherapy for Patients with Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis—a Randomized Study-Reference-Cited by-同舟云学术

Efficacy of Postoperative Transarterial Chemoembolization and Portal Vein Chemotherapy for Patients with Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis—a Randomized Study

Published:2006-10-04 Issue:11 Volume:30 Page:2004-2011
ISSN:0364-2313
Container-title:World Journal of Surgery
language:en
Short-container-title:World J. Surg.

Author:

Li Q.,Wang J.,Sun Y.,Cui Y.L.,Juzi J.T.,Li H.X.,Qian B.Y.,Hao X.S.

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

http://link.springer.com/content/pdf/10.1007/s00268-006-0271-6.pdf

Reference36 articles.

1. Zhang JY, Dai M, Wang X, et al. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol 1998;27:574–578

2. Chung YH, Song H, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-a for hepatocellular carcinoma patients with major poral vein thrombosis or distant metastasis. Cancer 2000;88:1986–1991

3. Qiang L, Huikai L, Butt K, et al. Factors associated with disease survival after surgical resection in Chinese patients with Hepatocellular Carcinoma. World J Surg 2006;30:1–7

4. Momosaki S, Nakashima Y, Kojiro M, et al. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. J Viral Hepat 2005;12:325–329

5. Tokita H, Fukui H, Tanaka A, et al. Related articles, links risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005;20:752–758

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study;HPB;2024-06

2. Survival benefit from adjuvant TACE combined with Lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy;Asian Journal of Surgery;2024-05

3. Survival benefit of perioperative locoregional adjuvant treatment for hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and Bayesian network meta-analysis;Critical Reviews in Oncology/Hematology;2023-09

4. Novel online calculator to predict reduced risk of early recurrence from adjuvant transarterial chemoembolisation for patients with hepatocellular carcinoma;eGastroenterology;2023-08

5. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study;European Journal of Surgical Oncology;2023-07